Evidence map›Paper›PMID 40794249›Full record

ArticleEuropean radiology experimental2025

MRI-derived quantification of hepatic vessel-to-volume ratios in chronic liver disease using a deep learning approach.

Alexander Herold, Daniel Sobotka, Lucian Beer, Nina Bastati, Sarah Poetter-Lang, Michael Weber, Thomas Reiberger, Mattias Mandorfer, Georg Semmler, Benedikt Simbrunner and 5 more

Abstract read
In one paragraph

Article in European radiology experimental, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Automated Deep Learning Detection of Hepatic Steatosis on Noncontrast Computed Tomography Scans and Discrepancy With Scan Reports.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Alexander Herold *Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
Daniel Sobotka *Computational Imaging Research Lab, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
Lucian BeerDepartment of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
Nina BastatiDepartment of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
Sarah Poetter-LangDepartment of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
Michael WeberDepartment of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
Thomas ReibergerDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
Mattias MandorferDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
Georg SemmlerDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
Benedikt SimbrunnerDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
Barbara D WichtmannDepartment of Neuroradiology, University Hospital Bonn, Bonn, Germany.
Sami A Ba-SsalamahDepartment of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
Michael TraunerDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
Ahmed Ba-SsalamahDepartment of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria. ahmed.ba-ssalamah@meduniwien.ac.at.ORCID http://orcid.org/0000-0002-3527-404X
Georg LangsDepartment of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.

Funding

HORIZON EUROPE Reforming and enhancing the European Research and Innovation system 101080302HORIZON EUROPE Reforming and enhancing the European Research and Innovation system 101136299
6 · The paper itself

Abstract

backgroundWe aimed to quantify hepatic vessel volumes across chronic liver disease stages and healthy controls using deep learning-based magnetic resonance imaging (MRI) analysis, and assess correlations with biomarkers for liver (dys)function and fibrosis/portal hypertension.

methodsWe assessed retrospectively healthy controls, non-advanced and advanced chronic liver disease (ACLD) patients using a 3D U-Net model for hepatic vessel segmentation on portal venous phase gadoxetic acid-enhanced 3-T MRI. Total (TVVR), hepatic (HVVR), and intrahepatic portal vein-to-volume ratios (PVVR) were compared between groups and correlated with: albumin-bilirubin (ALBI) and "model for end-stage liver disease-sodium" (MELD-Na) score) and fibrosis/portal hypertension (Fibrosis-4 (FIB-4) Score, liver stiffness measurement (LSM), hepatic venous pressure gradient (HVPG), platelet count (PLT), and spleen volume.

resultsWe included 197 subjects, aged 54.9 ± 13.8 years (mean ± standard deviation), 111 males (56.3%): 35 healthy controls, 44 non-ACLD, and 118 ACLD patients. TVVR and HVVR were highest in controls (3.9; 2.1), intermediate in non-ACLD (2.8; 1.7), and lowest in ACLD patients (2.3; 1.0) (p ≤ 0.001). PVVR was reduced in both non-ACLD and ACLD patients (both 1.2) compared to controls (1.7) (p ≤ 0.001), but showed no difference between CLD groups (p = 0.999). HVVR significantly correlated indirectly with FIB-4, ALBI, MELD-Na, LSM, and spleen volume (ρ ranging from -0.27 to -0.40), and directly with PLT (ρ = 0.36). TVVR and PVVR showed similar but weaker correlations.

conclusionDeep learning-based hepatic vessel volumetry demonstrated differences between healthy liver and chronic liver disease stages and shows correlations with established markers of disease severity. RELEVANCE STATEMENT: Hepatic vessel volumetry demonstrates differences between healthy liver and chronic liver disease stages, potentially serving as a non-invasive imaging biomarker. KEY POINTS: Deep learning-based vessel analysis can provide automated quantification of hepatic vascular changes across healthy liver and chronic liver disease stages. Automated quantification of hepatic vasculature shows significantly reduced hepatic vascular volume in advanced chronic liver disease compared to non-advanced disease and healthy liver. Decreased hepatic vascular volume, particularly in the hepatic venous system, correlates with markers of liver dysfunction, fibrosis, and portal hypertension.

Indexed as

Deep LearningHepatic VeinsLiver DiseasesLiver Function TestsMagnetic Resonance ImagingAdultAgedBiomarkersCase-Control StudiesChronic DiseaseContrast MediaFemaleGadolinium DTPAHemodynamicsHumansHypertension, PortalBiomarkersContrast MediaGadolinium DTPAgadolinium ethoxybenzyl DTPADeep learningEnd-stage liver diseaseHypertension (portal)Liver circulationMagnetic resonance imaging

Identifiers

PMID40794249
PMCPMC12343422

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.